

## Contact information

Professor Emerita  
Kristina Källén  
Lund University, Medical Faculty,  
Department of Clinical Sciences Lund-Helsingborg

Postal address:  
Paradisvägen 9  
26376 Nyhamnsläge  
Sweden

Email: [kristina.kallen@med.lu.se](mailto:kristina.kallen@med.lu.se)  
Mobile: +46732033167  
Web address: <http://www.med.lu.se/klinvetlund/neurologi>

## Former employments

### Professor emerita

Clinical Sciences, Helsingborg  
Lund University  
Helsingborg, Sweden  
2015 Mar 1 → present

### Neurology, Lund

Lund University  
Lund, Sweden  
2015 Sept 21 → present

### Project manager

Clinical Epilepsy Research  
Lund University  
Lund, Sweden  
2016 Aug 11 → present

### Affiliated researcher

Epilepsy Center  
Lund University  
Lund, Sweden  
2019 Feb 28 → present

1988 MD degree, University of Gothenburg, Sweden.  
1990 Authorized Physician in Sweden.  
1995 Registered Specialist in Neurology in Sweden.  
1996 Specialist examination in Neurology under the Auspices of the Swedish Society of Neurology and the Swedish Society of Medicine.  
1999 October 16th PhD in Neurology, Faculty of Medicine, Lund University  
2008 Associate Professor in Neurology, Faculty of Medicine, Lund University  
2021 Professor, internal medicine - Neurology, Faculty of Medicine, Lund University

## Foreign research appointment:

2000-2001 Research Fellowship. Epilepsy Section, Department of Neurology, the Cleveland Clinic Foundation, Cleveland, Ohio, USA.

## Current Academic positions

Professor emerita Neurology , Lund University, Medical Faculty, Department of Clinical Sciences in Lund, Division of Clinical Sciences Helsingborg

## Previous Honorary Commitments

Treasurer Swedish Neurological Society 1999-2001  
President Swedish Neurological Society 2002-2004  
Steering Committee, Swedish National Epilepsy Registry 2002-2015  
Board member Swedish Epilepsy Society 1999-2014  
President Swedish Epilepsy Society 2010-2013, Chapter International League Against Epilepsy  
The Swedish Ethics Review Authority  
Reviewer in the Swedish Ethics Review Authority

## Current Clinical position

Consultant MD Neurology section, Department of specialized clinical medicine 2, General hospital in Helsingborg, Sweden

## Current expert appointments

Professor emerita. Division of clinical sciences in Lund, Medical Faculty, Lund, Sweden

Reviewer and member of the advisory board of LIPUS (Läkarnas Institut för Professionell Utveckling i Sverige)

## RESEARCH

### Scientific supervision:

Approved and finalized projects:

2014. Principle supervisor of Maria Strandberg for her doctoral thesis "Advanced clinical MRI for better outcome in epilepsy surgery – focusing on prediction of verbal memory decline". Dissertation performed at Lund University.

2018. Principle supervisor of neuropsychologist Hanna Ljung for her doctoral thesis "Predictors of Verbal Memory Deficits from Temporal Lobe Surgery in Epilepsy. Improving patient selection by investigation of methods used for predicting verbal memory following surgery". Dissertation performed at Lund University.

2021. Principle supervisor of MD Patrik Olsson for his doctoral thesis "Generic drug switch in epilepsy - pharmacokinetic and clinical aspects". Dissertation performed at Lund University.

2024. Principle supervisor of MD Kevin Pearsson for his doctoral thesis "Epilepsy surgery in tuberous sclerosis complex : Utilisation, satisfaction, and outcomes". Dissertation performed at Lund University.

Former principle, and present assistant, supervisor of PhD students with ongoing projects:

Ariadni Zampeli, specialist in neurology. PhD project Accepted at LU 2017.

Johan Hellgren, MD. Phd project accepted by LU 2020.

Supervisor of 12 master degree projects 2012 - 2025.

### Opponent at doctoral dissertations:

2016. PhD student Simone Frizell Reiter. Thesis "Psychiatric disease, adverse social aspects, and quality of life in women and men with epilepsy related to pregnancy". University of Bergen, Norway.

2025. PhD Markus Karlander. Thesis "Post-traumatic epilepsy: Risk factors, Clinical insights, Socioeconomic aspects, and Prognosis." Gothenburg University, Sweden. Dissertation performed at the Medical Faculty at Sahlgrenska University.

Reviewer at the Half-time seminars:

2021. Sorina Gorcenco, Clinical and genetic studies on patients and families with ataxias.

2023. Margareta Lang, Head computed tomography for prediction of neurological outcome after cardiac arrest. Medical Faculty, Lund University.

Member of evaluating committee at doctoral dissertations:

2010. Malin Rundgren, Cardiac arrest and therapeutic hypothermia: Prognosis and outcome". Medical Faculty, Lund University.

2015. Torsten Danfors, 11C Molecular Imaging in focal epilepsy". Uppsala University.

2016. Gustav Torisson, Cognitive impairment in medical inpatients". Lund University.

2016. Irini Dragencea, Neurological prognostication after cardiac arrest and targeted temperature management". Lund University, 2016.

2017. Hossein Delavaran, Clinical findings and outcome after stroke". Lund University.

2021. Emil Ygland Rödström, Prognostic subtypes in Parkinson's disease and related disorders. Clinical, genetical and biochemical markers of long term social, motor, and cognitive development, Lund University.

2021. Joseph Aked. Stroke epidemiology and outcome in southern Sweden. Lund University.

2023. David Larsson, Acquired Epilepsy with a Focus on Stroke. Gothenburg University.

2023. Klara Andersson, Stigma and socioeconomic outcomes in epilepsy. Gothenburg University.  
2023. Sorina Gorcenco, Clinical and genetic studies on patients and families with ataxias, Lund University.  
2023. Samuel Håkansson. "Machine learning and big data for personalized epilepsy treatment. Gothenburg University.  
2025. Ameldina Ceric, Sedation and analgesia during intensive care after cardiac arrest. Lund University.

Suppleant member of the evaluation committee

Ingela Ahnlide "Aspects on skin cancer diagnosis in clinical practice", Lund University 2015

Yulia Sorova "Magnetic Resonance Imaging in Parkinson's disease and related disorders", Lund University, 2018.

Referee appointments:

Epilepsia, J of Clin Neurol and Neurosurg, Acta Neurol Scand, The Scand J of Clin and Lab Invest, J of Neurology, J Epilepsy Research, Läkartidningen, J Multiple Sclerosis and Related Disorders, J Epilepsy & Behavior, and others...

## GCP authorized PI in clinical drug trials

1. A multicentre, randomised, double-blind, placebo controlled, phase III study of subcutaneous Rebif (recombinant human interferon-beta) in the treatment of relapsing remitting multiple sclerosis. (Serono) 2. An open randomised, parallel-group comparison of tiagabine BID versus TID as adjunctive treatment of partial seizures in patients with epilepsy. (Novo-Nordisk) 3. A multicenter, double-blind, randomised, parallel-group, positive-controlled trial comparing the efficacy and safety of levetiracetam (1000 to 3000 mg/day oral b.i.d.) to carbamazepine (400 to 1200 mg/day oral b.i.d.) used as monotherapy up to a maximum of 121 weeks in subjects (> 16 years) newly or recently diagnosed as suffering from epilepsy, and experiencing partial or generalized tonic-clonic seizures. (UCB Pharma) 4. PRI/TOP-INT-11 Topiramate monotherapy comparison trial to standard monotherapy in the treatment of newly diagnosed epilepsy (RWJ-17021-000. (Janssen-Cilag) 5. The Nelly study (Vikt och menstruationsstörningar hos kvinnor med monoterapi mot epilepsi; GlaxoSmithKline) 6. Gabapentin versus vigabatrin as first add-on for patients with partial seizures that failed to respond to monotherapy: a randomized, double-blind, dose titration study. GREAT Study Investigators Group. Gabapentin in Refractory Epilepsy Add-on Treatment. (Parke-Davis) 7. Open multicenter randomized comparison of cognitive effects of lamotrigine and slow-release carbamazepine monotherapy in newly diagnosed patients with partial epilepsy. (Glaxo-Wellcome) 8. Keppra Study N01061. A multi-centre, double-blind, randomized, parallel group, positive-controlled trial comparing the efficacy and safety of levetiracetam to carbamazepine, used as monotherapy in subjects newly or recently diagnosed as suffering from epilepsy, and experiencing partial or generalized tonic-clonic seizures. (UCB) 9. NS 1209-007. A phase II, multi-centre, single-blinded, randomised, parallel group study to determine the efficacy of NS1209 compared to standard treatment in acute treatment of patients in refractory partial status epilepticus. (NeuroSearch) 10. A randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate the efficacy, safety, and tolerability of RWJ-333369 as adjunctive therapy in subjects with partial onset seizures followed by an open-label extension study. (Janssen Cilag) 11. A phase III randomized, multi-centre, double-blind study, to compare the efficacy and safety of zonisamide and carbamazepine as monotherapy, in newly diagnosed partial epilepsy. (Eisai) 12. MAZE STUDY. A phase III randomized, double-blind extension study to assess the long-term safety and to explore the long-term efficacy of zonisamide as monotherapy in newly diagnosed partial seizures. (Eisai). 13. Phase III international, double-blind, randomized, multi-center, parallel group, historical-control conversion to monotherapy study to evaluate the efficacy and safety of brivaracetam in subjects with partial onset seizures with or without secondary generalization. (UCB)